Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection | Zendy

Kun Li | Zendy; Zhuo Li | Zendy; Christine Wohlford-Lenane | Zendy; David K. Meyerholz | Zendy; Rudragouda Channappanavar | Zendy; Dong An | Zendy; Stanley Perlman | Zendy; Paul B. McCray | Zendy; Biao He | Zendy

Open Access

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

Author(s) -

Kun Li,

Zhuo Li,

Christine Wohlford-Lenane,

David K. Meyerholz,

Rudragouda Channappanavar,

Dong An,

Stanley Perlman,

Paul B. McCray,

Biao He

Publication year - 2020

Publication title -

mbio

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.562

H-Index - 121

eISSN - 2161-2129

pISSN - 2150-7511

DOI - 10.1128/mbio.00554-20

Subject(s) - virology , middle east respiratory syndrome coronavirus , immunization , nasal administration , coronavirus , medicine , covid-19 , recombinant dna , biology , immunology , antibody , infectious disease (medical specialty) , disease , pathology , biochemistry , gene

MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research